Impact of intravenous omeprazole on Helicobacter pylori eradication by triple therapy in patients with peptic ulcer bleeding

doi:10.1046/j.1365-2036.2002.01137.x

If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.

It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.

Wiley InterScience

Alimentary Pharmacology & Therapeutics

Volume 16 Issue 1, Pages 137 - 143

Published Online: 11 Jan 2002

< Previous Abstract | Next Abstract >

Save Article to My Profile Download Citation Request Permissions

Abstract | References | Full Text: HTML, PDF (Size: 219K) | Related Articles | Citation Tracking

Impact of intravenous omeprazole on Helicobacter pylori eradication by triple therapy in patients with peptic ulcer bleeding

B.-S. Sheu ¹ , C.-H. Chi ² , C.-C. Huang ⁴ , A.-W. Kao ¹ , Y.-L. Wang ⁵ & H.-B. Yang ³

¹ Department of Internal Medicine, National Cheng Kung University, Tainan, Taiwan, ² Department of Emergency Medicine, National Cheng Kung University, Tainan, Taiwan, ³ Department of Pathology, National Cheng Kung University, Tainan, Taiwan, ⁴ Institute of Clinical Pharmacology, National Cheng Kung University, Tainan, Taiwan, ⁵ Chung Hwa College of Medical Technology, Tainan, Taiwan

Correspondence to: Dr B.-S. Sheu, Department of Internal Medicine, National Cheng Kung University Hospital, 138 Sheng Li Road, Tainan, 70428, Taiwan. E-mail: sheubs@mail.ncku.edu.tw

ABSTRACT

Aim:

To test the impact of intravenous omeprazole on Helicobacter pylori eradication for bleeding peptic ulcers.

Methods:

A total of 175 H. pylori-infected patients with bleeding peptic ulcers were randomized into either an omeprazole group or a ranitidine group, receiving intravenous omeprazole or ranitidine for 3 days after endoscopy. Afterwards, 1-week triple therapy was used to eradicate H. pylori for both groups. Six weeks later, either a ¹³C-urea breath test or follow-up endoscopy was performed to assess the success of H. pylori eradication.

Results:

The rebleeding rate was lower in the omeprazole group vs. the ranitidine group (6% vs. 17%, P < 0.05). The H. pylori eradication rate was higher in the omeprazole group (intention-to-treat analysis: 83% vs. 66%, P < 0.05; per protocol analysis: 93% vs. 80%, P < 0.05). For patients with duodenal ulcers, the per protocol H. pylori eradication rate of the omeprazole group was higher than that of the ranitidine group (93% vs. 73%, P < 0.05).

Conclusions:

Intravenous omeprazole can decrease the risk of rebleeding of peptic ulcers. For duodenal ulcers, in particular, intravenous omeprazole may even improve the H. pylori eradication rate of the subsequent triple therapy.

DIGITAL OBJECT IDENTIFIER (DOI)

10.1046/j.1365-2036.2002.01137.x About DOI